Factor Xa inhibitors

Bibliography

• DAVIE E, FUJIKAWA K, KISIEL W: The coagulation cascade: initiation, maintenance, and regulation. Biochemistry (1991) 30:10363–10370.
   PubMed Web of Science ®Google Scholar
• ESMON C: Cell mediated events that control bloodcoagulation and vascular injury. Ann. Rev. Cell Biol. (1993) 9:1–26.
   PubMedGoogle Scholar
• VERSTRAETE M, ZOLDHELYI P: Novel antithromboticdrugs in development. Drugs (1995) 49:856–884.
   PubMed Web of Science ®Google Scholar
• LEFKOVITS J, TOPOL E: Direct thrombin inhibitors incardiovascular medicine. Circulation (1 9 9 4) 90:1522-1536.
   Google Scholar
• PHILIPPIDES G, LOSCALZO J: Potential advantages ofdirect-acting thrombin inhibitors. Coron. Artery Dis. (1996) 7:497–507.
   PubMedGoogle Scholar
• FAREED J, CALLAS D, HOPPENSTEADT D et al: Recentdevelopments in antithrombotic agents. Exp. Opin. Invest. Drugs (1995) 4(5):389–412.
   Google Scholar
• FITZGERALD D: Specific thrombin inhibitors in vivo. Ann. NY Acad. ScL (1994) 714:41–52.
   PubMed Web of Science ®Google Scholar
• KIMBALL S: Challenges in the development of orally bioavailable thrombin active site inhibitors. Blood Coagul. Fibrinolysis (1995) 6:511–519.
   PubMed Web of Science ®Google Scholar
• DAS J, KIMBALL S: Thrombin active site inhibitors.Bioorg. Med. Chem. (1995) 3:999–1007.
   PubMed Web of Science ®Google Scholar
• WILEY M, FISHER M: Small molecule direct thrombin inhibitors. Exp. Opin. Ther. Patents (1 9 9 7) 7(10:1265-1282.
   Google Scholar
• NEUHAUS K, VON ESSEN R, TEBBE U et al.: Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis study. Circulation (1994) 90:1638–1642.
   PubMed Web of Science ®Google Scholar
• GUSTO IIA INVESTIGATORS: Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strate-gies to Open Occluded Coronary Arteries (GUSTO) Ha Investigators. Circulation (1994) 90:1631–1637.
   Google Scholar
• ANTMAN E: Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation (1994) 90:1624–1630.
   Google Scholar
• CLAESON G: Synthetic peptides and peptidomimetics as substrates and inhibitors of thrombin and other proteases in the blood coagulation system. Blood Coagul. Fibrinolysis (1994) 5:411–436.
   PubMedGoogle Scholar
• SCARBOROUGH R: Anticoagulant strategies targeting thrombin and Factor Xa. Ann. Report Med. Chem. (1995) 30:71–80.
   Google Scholar
• EDMUNDS J, RAPUNDAL S, SIDDIQUI M: Thrombin and Factor Xa inhibition. Ann. Report Med. Chem. (1996) 31:51–60.
   Web of Science ®Google Scholar
• ••Good recent review of antithrombotics.
   Google Scholar
• POWERS J, HARPER J: Inhibitors of serine proteinases. In: Proteinase Inhibitors. Barrett AJ, Salvesen (Eds.), Elsevier Science Publishers BV (Biomedical Division), New York, USA (1986):55–152.
   Google Scholar
• KAISER B, HAUPTMANN J: Factor Xa inhibitors as novel antithrombotic agents: facts and perspectives. Cardio-vasc. Drug Rev. (1994) 12:225–236.
   Google Scholar
• DUNWIDDIE C, WAXMAN L, VLASUK G, FRIEDMAN P: Purification and characterization of inhibitors of blood coagulation Factor Xa from hematophagous organisms. Methods Enzymol. (1993) 223:291–312.
   PubMedGoogle Scholar
• DUNWIDDIE C, THORNBERRY N, BULL H et al.: Antistasin, a leech-derived inhibitor of Factor Xa. Kinetic analysis of enzyme inhibition and identifica-tion of the reactive site. J. Biol. Chem. (1989) 264:16694–16699.
   Google Scholar
• •Discovery of natural inhibitor of Factor Xa.
   Google Scholar
• OHTA N, BRUSH M, JACOBS J: Interaction of antistasin- related peptides with Factor Xa: identification of a core inhibitory sequence. Thromb. Haemost. (19 9 4) 72:825–830.
   Google Scholar
• JORDAN S, MAO S, LEWIS S, SHAFER J: Reaction pathway for inhibition of blood coagulation Factor Xa by tick anticoagulant peptide. Biochemistry (1992) 31:5374–5380.
   PubMed Web of Science ®Google Scholar
• VLASUK G: Structural and functional characterization of tick anticoagulant peptide (TAP): a potent and selective inhibitor of blood coagulation Factor Xa. Thromb. Haemost. (1993) 70:212–216.
   PubMed Web of Science ®Google Scholar
• BETZ A, VLASUK G, BERGUM P, KRISHNASWAMY S: Selective inhibition of the prothrombinase complex: Factor Va alters macromolecular recognition of a tick anticoagulant peptide mutant by Factor Xa. Biochem-istry (1997) 36:181–191.
   PubMedGoogle Scholar
• MAO S, HUANG J, WELEBOB C et al.: Identification and characterization of variants of tick anticoagulant peptide with increased inhibitory potency toward human Factor Xa. Biochemistry (1995) 34:5098–5103.
   PubMed Web of Science ®Google Scholar
• SCHAFFER L, DAVIDSON J, VLASUK G, SIEGL P: Antithrombotic efficacy of recombinant tick antico-agulant peptide. A potent inhibitor of coagulation Factor Xa in a primate model of arterial thrombosis. Circulation (1991) 84:1741–1748.
   Google Scholar
• VLASUK G, RAMJIT D, FUJITA T et al.: Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective Factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis. Thromb. Haemost. (1991) 65:257–262.
   PubMed Web of Science ®Google Scholar
• SITKO G, RAMJIT D, STABILITO I et al.: Conjunctive enhancement of enzymatic thrombolysis and preven-tion of thrombotic reocclusion with the selective Factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis. Circulation (1992) 85:805–815.
   Google Scholar
• MELLOTT M, STRANIERI M, SITKO G et al.: Enhancement of recombinant tissue plasminogen activator-induced reperfusion by recombinant tick anticoagulant peptide, a selective Factor Xa inhibitor, in a canine model of femoral arterial thrombosis. Fibrinolysis (1993) 7:195–202.
   Google Scholar
• FIORAVANTI C, BURKHOLDER D, FRANCIS B et al.: Antithrombotic activity of recombinant tick antico-agulant peptide and heparin in a rabbit model of venous thrombosis. Thromb. Res. (1993) 71:317–324.
   PubMedGoogle Scholar
• ••Shows the superiority of Factor Xa inhibition relative toheparin.
   Google Scholar
• LYNCH JJ, SITKO G, LEHMAN E, VLASUK G: Primary prevention of coronary arterial thrombosis with the Factor Xa inhibitor rTAP in a canine electrolytic injury model. Thromb. Haemost. (1995) 74:640–645.
   PubMedGoogle Scholar
• RIGBI M, JACKSON C, ATAMNA H et al.: FXa inhibitor from the saliva of the leech Hirudo medicinalis. Thromb. Haemost. (1995) 73:1558.
   Google Scholar
• WERBER M, ZEELON E, LEVANON A et al.: Yagin, a leech derived FXa inhibitor, expressed in and recovered from E. coli: Anti-thrombotic potency in vitro and in vivo. Thromb. Haemost. (1995) 73: 1582.
   Google Scholar
• KORNOWSKI R, ELDOR A, WERBER M et al: Enhance-ment of recombinant tissue-type plasminogen activator thrombolysis with a selective Factor Xa inhibitor derived from the leech Hirudo medicinalis: Comparison with heparin and hirudin in a rabbit thrombosis model. Coron. Artery Dis. (1996) 7:903–909.
   PubMedGoogle Scholar
• APITZ-CASTRO R, BEGUIN S, TABLANTE A et al.: Purifica-tion and partial characterization of draculin, the anticoagulant factor present in the saliva of vampire bats (Desmodus rotundus). Thromb. HaemosL (1995) 73:94–100.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ A, TABLANTE A, BARTOLI F et al.: Expres-sion of biological activity of draculin, the anticoagu-lant factor from vampire bat saliva, is strictly dependent on the appropriate glycosylation of the native molecule. Biochim. Biophys. Acta (1998) 1425:291–299.
   PubMedGoogle Scholar
• SEYMOUR J, LINDQUIST R, DENNIS M et al.: Ecotin is a potent anticoagulant and reversible tight-binding inhibitor of Factor Xa. Biochemistry (1994) 33:3949–3958.
   PubMed Web of Science ®Google Scholar
• GIRARD T, WARREN L, NOVOTNY W et al: Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature (1989) 338:518–520.
   PubMed Web of Science ®Google Scholar
• JESKE W, HOPPENSTEADT D, CALLAS D et al.: Pharma-cological profiling of recombinant tissue factor pathway inhibitor. Semin. Thromb. HemosL (1996) 22:213–219.
   PubMed Web of Science ®Google Scholar
• STANSSENS P, BERGUM P, GANSEMANS Y et al: Antico-agulant repertoire of the hookworm Ancylostoma caninum. Proc. Natl. Acad. ScL USA (1996) 93:2149–2154.
   PubMed Web of Science ®Google Scholar
• REBELLO S, BLANK H, ROTE W et al: Antithrombotic efficacy of a recombinant nematode anticoagulant peptide (rNAP5) in canine models of thrombosis after single subcutaneous administration. J. Pharmacol Exp. Ther. (1997) 283:91–99.
   PubMedGoogle Scholar
• NAGAHARA T, YOKOYAMA Y, INAMURA K et al.: Dibasic (amidinoaryl)propanoic acid derivatives as novel blood coagulation Factor Xa inhibitors. J Med. Chem. (1994) 37:1200–1207.
   PubMed Web of Science ®Google Scholar
• ••Synthesis of small molecule non-peptide Factor Xa inhibitorDX-9065A.
   Google Scholar
• HARA T, YOKOYAMA A, ISHIHARA H et al: DX-9065A, a new synthetic, potent anticoagulant and selective inhibitor for Factor Xa. Thromb. HaemosL (1994) 71:314–319.
   PubMed Web of Science ®Google Scholar
• YOKOYAMA T, KELLY AB, MARZEC UM et al.: Antithrom-botic effects of orally active synthetic antagonist of activated Factor Xa in nonhuman primates. Circulation (1995) 92:485–491.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI M, ASAKURA H, AOSHIMA K et al.: Protective effects of DX-9065A, an orally active, novel synthe-sized and selective inhibitor of Factor Xa, against thromboplastin-induced experimental disseminated intravascular coagulation in rats. Semin. Thromb. HemosL (1996) 22:255–259.
   PubMed Web of Science ®Google Scholar
• STUBBS MT, HUBER R, BODE W: Crystal structures of Factor Xa specific inhibitors in complex with trypsin: structural grounds for inhibition of Factor Xa and selectivity against thrombin. FEBS Letts. (1995) 375:103–107.
   PubMed Web of Science ®Google Scholar
• BRANDSTETTER H, KUHNE A, BODE W et al.: X-ray structure of active site-inhibited clotting Factor Xa. Implications for drug design and substrate recogni-tion. J. Biol. Chem. (1996) 47:29988–29992.
   Google Scholar
• LIN Z, JOHNSON ME: Proposed cation-mediatedbinding by Factor Xa: a novel enzymatic mechanism for molecular recognition. FEBS Lett. (1995) 370:1–5.
   PubMedGoogle Scholar
• •Importance of cation-It interaction in Factor Xa inhibitors design.
   Google Scholar
• KUNITADA S, NAGAHARA T, HARA T: Inhibitors of Factor Xa. In: Handbook of Experimental Pharmacology (Antithrombotic). Springer, New York, USA (1999) 132:397–429.
   Google Scholar
• KAMATA K, KAWAMOTO H, HONMA T et al.: Structuralbasis for chemical inhibition of human blood coagula-tion Factor Xa. Proc. Natl. Acad. Sci. USA (1998) 95:6630–6635.
   PubMed Web of Science ®Google Scholar
• MARKWARDT F, HAUPTMANN J: Synthetic thrombin inhibitors as anticoagulants pharmacological aspects. Adv. Exp. Med. Biol. (1993) 340:143–171.
   PubMedGoogle Scholar
• SHAW K, GUILFORD W, DALLAS J et al.: (Z,Z)-2,7-Bis(4-amidinobenzylidene) cycloheptan-1-one: identification of a highly active inhibitor of blood coagulation Factor Xa. J. Med. Chem. (1998) 41:3551–3556.
   PubMedGoogle Scholar
• CASALE E, COLLYER C, ASCENZI P et al.: Inhibition of bovine beta-trypsin, human alpha-thrombin and porcine pancreatic beta-kallikrein-B by 4',6-diamidino-2-phenylindole, 6-amidinoindole and benzamidine: a comparative thermodynamic and x-ray structural study. Biophys. Chem. (1995) 54:75–81.
   PubMedGoogle Scholar
• ASCENZI P, FRUTTERO R, AMICONI G et al.: Inhibition of human alpha-, beta- and gamma-thrombin by mono-, bis-, tris- and tetra-benzamidine structures: thermody-namic study. J. Enzyme Inhib. (1992) 6:131–139.
   PubMed Web of Science ®Google Scholar
• STURZEBECHER J, STURZEBECHER U, VIEWEG H et al.: Synthetic inhibitors of bovine Factor Xa and thrombin comparison of their anticoagulant efficiency. Thromb. Res. (1989) 54:245–252.
   PubMed Web of Science ®Google Scholar
• PHILLIPS G, BUCKMAN B, DAVEY D et al.: Discovery of Is1[2-[54Amino(imino)methy11-2-hydroxyphenoxy]-3, 5- difluoro-643-(4, 5-dihydro-1-methyl-1H-imidazol-2 -y1) phenoxylpyridin-4-y1I-N-methylglycine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme Factor Xa. J. Med. Chem. (1998) 41:3557–3562.
   PubMed Web of Science ®Google Scholar
• XU W, DAVEY D, EAGEN K et al.: Design, synthesis and biological activity of novel Factor Xa inhibitors. 3. 215th ACS Meeting. Dallas, USA (1998). MEDI–123.
   Google Scholar
• NG H, BUCKMAN B, DAVEY D et al.: Design, synthesis and biological activity of novel Factor Xa inhibitors. 4. 215th ACS Meeting. Dallas, USA (1998). MEDI–124.
   Google Scholar
• DAVEY D, BUCKMAN B, EAGEN K et al. Design, synthesis and biological activity of novel Factor Xa inhibitors. 5. 215th ACS Meeting. Dallas, USA (1998). MEDI–125.
   Google Scholar
• BUCKMAN B, MOHAN R, KOOVAKKAT S et al.: Design, synthesis, and biological activity of novel purine and bicyclic pyrimidine Factor Xa inhibitors. Bioorg. Med. Chem. Lett. (1998) 8:2235–2240.
   PubMed Web of Science ®Google Scholar
• ZHAO Z, SHAW K, WHITLOW M et al.: Design, synthesis and biological activity of novel Factor Xa inhibitors. 7. 215th ACS Meeting. Dallas, USA (1998). MEDI–127.
   Google Scholar
• ARNAIZ D, CHOU Y, MOHAN R et al.: Design, synthesis and biological activity of novel Factor Xa inhibitors. 8. 215th ACS Meeting. Dallas, USA (1998). MEDI–128.
   Google Scholar
• GRIEDEL B, ARNAIZ D, SAKATA S et al.: Design, synthesis and biological activity of novel Factor Xa inhibitors. 9. 215th ACS Meeting. Dallas, USA (1998). MEDI–129.
   Google Scholar
• CHOU Y, GUILFORD W, KOOVAKKAT S et al: Design, synthesis and biological activity of novel Factor Xa inhibitors. 215th ACS Meeting. Dallas, USA (1998). MEDI–130.
   Google Scholar
• BRANDSTETTER H, KUHNE A, BODE W et al: X-ray structure of active site-inhibited clotting Factor Xa. Implications for drug design and substrate recogni-tion. J. Biol. Chem. (1996) 271:29988–29992.
   Google Scholar
• KUCZNIERZ R, GRAMS F, LEINERT H et al.: Tetrahydro-isoquinoline-based Factor Xa inhibitors. J. Med. Chem. (1998) 41:4983–4994.
   PubMed Web of Science ®Google Scholar
• SAWYER T: Peptidomimetic and nonpeptide drug discovery: Impact of structure-based drug design. In: Structure-based Drug Design: Diseases, Targets, Techniques and Developments. Veerapandian P (Ed.), Marcel Dekker, Inc., New York, USA (1997):559–634.
   Google Scholar
• MADUSKUIE TJ, MCNAMARA K, RU Y et al.: Rational design and synthesis of novel, potent bis-phenylamidine carboxylate Factor Xa inhibitors. J. Med. Chem. (1998) 41:53–62.
   PubMed Web of Science ®Google Scholar
• CACCIOLA J, FEVIG J, STOUTEN P, ALEXANDER R: Synthesis and activity studies of conformationally restricted alpha-ketoamide Factor Xa inhibitors. 216th ACS Meeting. Boston, USA (1998). MEDI–78.
   Google Scholar
• PRUITT J, PINTO D, QUAN M et al.: Isoxazolines and isoxazoles as Factor Xa inhibitors. 216th ACS Meeting. Boston, USA (1998). MEDI–77.
   Google Scholar
• BOSTWICK J, BENTLEY R, MORGAN S et al: RPR120844, a novel, specific inhibitor of coagulation Factor Xa inhibits venous thrombosis in the rabbit. Thromb. Haemost. (1999) 81:157–160.
   PubMedGoogle Scholar
• CHOI-SLEDESKI YM, PAULS HW, BECKER MR et al.: Design, structure activity relationships and initial biological activity of novel non-benzamidine inhibi-tors of Factor Xa. 217th ACS Meeting. Anaheim, USA (1999). MEDI–080.
   Google Scholar
• •Another example of non-amidine or guanidine containing Factor Xa inhibitor.
   Google Scholar
• KLEIN S, CZEKAJ M, GARDNER C eta].: Identification and initial structure-activity relationships of a novel class of nonpeptide inhibitors of blood coagulation Factor Xa. J. Med. Chem. (1998) 41:437–450.
   Google Scholar
• FEVIG J, BURIAK JJ, CACCIOLA J et al: Rational design of boropeptide thrombin inhibitors: beta, beta-dialkyl-phenethylglycine P2 analogs of DuP 714 with greater selectivity over complement Factor I and an improved safety profile. Bioorg. Med. Chem. Lett. (1998) 8:301–306.
   PubMed Web of Science ®Google Scholar
• OSTREM J, AL-OBEIDI F, SAFAR P et al: Discovery of a novel, potent, and specific family of Factor Xa inhibi-tors via combinatorial chemistry. Biochemistry (1998) 37:1053–1059.
   PubMed Web of Science ®Google Scholar
• STRINGER SK, OSTREM JA, AL-OBEIDI F et al.: Antithrom-botic activity of an orally available, low molecular weight Factor Xa inhibitor derived from combinato-rial libraries. Thromb. Haemost. (1999). (Submitted).
   Google Scholar
• HIRAYAMA F, KOSHIO H, TANIUCHI Y et al.: Synthesis and structure-activity relationships of N-[(7-amidino-2-naphthyfi-methyl]amide derivatives: potent and orally active FXa inhibitors. 214th ACS Meeting Las Vegas, USA (1997). MEDI–49.
   Google Scholar
• TANIUCHI Y, SAKAI Y, HISAMICHI N et al.: Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human Factor Xa. Thromb. Haemost. (1998) 79:543–548.
   PubMed Web of Science ®Google Scholar
• SATO K, KAWASAKI T, HISAMICHI N et al.: Antithrom-botic effects of YM-60828, a newly synthesized Factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time. J. Pharmacol (1998) 123:92–96.
   Google Scholar
• SATO K, KAKU S, HIRAYAMA F et al.: Antithrombotic effect of YM-75466 is separated from its effect on bleeding time and coagulation time. Eur. J. Pharmacol (1998) 352:59–63.
   PubMed Web of Science ®Google Scholar
• SATO K, TANIUCHI Y, KAWASAKI T et al: Relationship between the antithrombotic effect of YM-75466, a novel Factor Xa inhibitor, and coagulation parameters in rats. Eur. j Pharmacol (1998) 347:231–236.
   PubMed Web of Science ®Google Scholar